Fundraising FoxNantOmics
Culver City, US · Founded 2012 · Delaware LLC
Find your way into NantOmics
Sign up to see every warm intro you have to NantOmics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NantOmics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NantOmics provides molecular testing for cancer, using an integrated panomic approach that combines DNA sequencing, RNA sequencing, and quantitative proteomics to profile a patient's tumor. Its analytical platform delivers molecular diagnostics and decision support to match cancer patients and their providers with targeted treatment options.
Founders & leadership
NantOmics was founded in 2012 by Patrick Soon-Shiong.
PS
Patrick Soon-ShiongFounder
Reported raises · per SEC filings
Form D private placements$260.9M disclosed across 4 rounds · 2015
▶$906.6KraisedSep 2015 · 1 investors · BiotechnologyRule 506(b)
▶$906.6KraisedSep 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Soon-ShiongDirector
- Offering amount
- $906.6K
- Amount sold
- $906.6K
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
▶$150MraisedSep 2015 · 1 investors · BiotechnologyRule 506(b)
▶$150MraisedSep 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Soon-ShingDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
▶$100MraisedJul 2015 · 1 investors · BiotechnologyRule 506(b)
▶$100MraisedJul 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Soon-ShiongDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
▶$10MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Soon-ShiongDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Jan 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
VerinomicsVerinomics develops crop improvement technology by combining genomics, computational biology, and a transgene-free gene editing platform, with an AI-driven population genomics tool to identify high-value trait genes. It serves breeding programs, agricultural businesses, and research institutions focused on specialty and vegetatively propagated crops such as leafy greens.
TagomicsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
Phenomic AIPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Nomic BioNomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.
PrognomIQPrognomiQ is a clinical-stage company developing blood-based tests for early detection and treatment of cancer and other complex diseases using multi-omics data. It combines proprietary large-scale proteomic data with genomic, metabolomic, and other health data on its own platform to build diagnostic test products.
CompleteomicsComplete Omics develops a clinical proteomics platform that identifies patient-specific neoantigens to enable personalized cancer therapeutics. The platform guides the design of targeted treatments such as mRNA vaccines and cell therapies.
Taconic BiosciencesTaconic Biosciences provides genetically engineered mouse and rat models, humanized immune system mice, custom model generation, colony management, and in vivo research services. It serves drug discovery and preclinical researchers, offering integrated laboratory animal models and services from model selection through study-ready cohorts.
Los Angeles Business Journal,This article covers the Chapter 11 bankruptcy auction process for Oceanwide Plaza, a $1.2 billion mixed-use development in downtown Los Angeles comprising residential towers, a hotel, and retail space that has remained incomplete since 2018.
Companies working in the same space as NantOmics.
Frequently asked questions
- What does NantOmics do?
- NantOmics provides molecular testing for cancer, using an integrated panomic approach that combines DNA sequencing, RNA sequencing, and quantitative proteomics to profile a patient's tumor. Its analytical platform delivers molecular diagnostics and decision support to match cancer patients and their providers with targeted treatment options.
- Who founded NantOmics?
- NantOmics was founded by Patrick Soon-Shiong in 2012.
- How much funding has NantOmics raised?
- NantOmics has disclosed $260.9M raised across 4 rounds.
- Where is NantOmics headquartered?
- NantOmics is headquartered in Culver City, US.